Tesamorelin 10mg Research Profile

Current catalog abstract

Documented material overview

Tesamorelin is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH), composed of a 44-amino acid sequence that has been structurally modified to enhance molecular stability and resistance to enzymatic degradation. This modification allows tesamorelin to retain biological activity for extended periods when compared with native GHRH, making it a compound of interest within controlled laboratory and investigative research environments. Initially developed and later approved under the brand name Egrifta®, tesamorelin has since attracted broader scientific attention due to its role in regulating endogenous growth hormone signaling pathways. In research settings, it has been evaluated for its influence on growth hormone pulsatility, insulin-like growth factor-1 (IGF-1) modulation, and observed changes in visceral adipose tissue distribution within studied populations. These findings have positioned tesamorelin as a relevant compound in metabolic, endocrine, and age-related physiology research models. Tesamorelin 10mg (10 vials) supplied for research purposes is manufactured to meet high analytical standards. It is typically provided as a high-purity, LPS-free peptide, verified as an endotoxin-free peptide, and classified under research peptides endotoxin tested protocols. These quality attributes support reproducibility, consistency, and integrity across experimental and laboratory investigations. Importantly, Tesamorelin is not intended for human or animal use. It is supplied strictly for laboratory, educational, and investigative research purposes only.